Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Paroxetine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 3/20 | 0.96 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | GRK2 | P25098 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.96 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.96 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.96 |
| ▸ | NPC1 | O15118 | 1/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Paroxetine SCHEMBL7247758 | 1.00 | CYP3A4 (1.00) | CYP3A4GRK2MEN1KMT2ATP53 | |
| Paroxetine SCHEMBL27521044 | 1.00 | CYP3A4 (1.00) | CYP3A4GRK2MEN1KMT2ATP53 | |
| Paroxetine SCHEMBL145267 | 1.00 | CYP3A4 (1.00) | CYP3A4GRK2MEN1KMT2ATP53 | |
| Paroxetine SCHEMBL27386741 | 0.99 | CYP3A4 (0.98) | CYP3A4GRK2MEN1KMT2ATP53 | |
| Paroxetine SCHEMBL33348 | 0.99 | CYP3A4 (1.00) | CYP3A4GRK2MEN1KMT2ATP53 | |
| Paroxetine SCHEMBL9398356 | 0.99 | CYP3A4 (1.00) | CYP3A4GRK2MEN1KMT2ATP53 | |
| Paroxetine SCHEMBL3854638 | 0.99 | CYP3A4 (1.00) | CYP3A4GRK2MEN1KMT2ATP53 | |
| Paroxetine SCHEMBL3461989 | 0.99 | CYP3A4 (0.98) | CYP3A4GRK2MEN1KMT2ATP53 | |
| Paroxetine SCHEMBL18937018 | 0.99 | CYP3A4 (0.98) | CYP3A4GRK2MEN1KMT2ATP53 | |
| Paroxetine SCHEMBL2847926 | 0.99 | CYP3A4 (1.00) | CYP3A4GRK2MEN1KMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 495 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9138430-B2 | Formulation and method for the release of paroxetine in the large intestine | MYLAN SPECIALTY L.P. (US) | 2015-09-22 | — | — | US | claimed |
| WO-2009138999-A2 | PROCESS FOR THE PREPARATION OF PAROXETINE HYDROCHLORIDE | MATRIX LABORATORIES LTD. (IN) | 2009-11-19 | — | — | WO | claimed |
| US-20090169616-A1 | FORMULATION AND METHOD FOR THE RELEASE OF PAROXETINE IN THE LARGE INTESTINE | MYLAN INC. | 2009-07-02 | — | — | US | claimed |
| US-20080292696-A1 | Enteric Sustained-Release Tablet Comprising Paroxetine | GL PHARMTECH CORP. (KR) | 2008-11-27 | — | — | US | claimed |
| EP-1726591-B1 | Process for manufacturing paroxetine hydrochloride hemihydrate | APOTECNIA S A (ES) | 2008-09-10 | — | — | EP | claimed |
| US-20080187584-A1 | Stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof | TEVA PHARMACEUTICALS USA, INC. | 2008-08-07 | — | — | US | claimed |
| US-7357945-B2 | Stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-04-15 | — | — | US | claimed |
| WO-2007052877-A1 | AN ENTERIC SUSTAINED-RELEASE TABLET COMPRISING PAROXETINE | GL PHARMTECH CORP. (KR) | 2007-05-10 | — | — | WO | claimed |
| WO-2007012968-A2 | STABLE DOSAGE FORM OF AN ANTIDEPRESSANT | AUROBINDO PHARMA LTD (IN) | 2007-02-01 | — | — | WO | claimed |
| US-20060287325-A1 | Combinations of paroxetine and 2-(r)-(4-fluoro-2-methyl-phenyl)-4-(s)-((8as)-6-oxo-hexahydro-pyrrolo'1,2-a!-pyrazin-2-yl)-piperidine-1-carboxylicacid'1-(r)-(3,5-bis-trifluoromethyl-phenyl)- | GLAXO GROUP LIMITED | 2006-12-21 | — | — | US | claimed |
| EP-0923554-A1 | N-BENZYLPIPERIDINE AND TETRAHYDROPYRIDINE DERIVATIVES | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1999-06-23 | — | — | EP | claimed |
| US-5856493-A | Process for making novel form of paroxeting hydrochloride anhydrate | SMITHKLINE BEECHAM CORPORATION (US) | 1999-01-05 | — | — | US | claimed |
| WO-1998001424-A1 | N-BENZYLPIPERIDINE AND TETRAHYDROPYRIDINE DERIVATIVES | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 1998-01-15 | — | — | WO | claimed |
| CN-1145586-A | Taste masking compositions comprising drug/polymer complexes | SMITHKLINE BEECHAM FARMA (IT) | 1997-03-19 | — | — | CN | claimed |
| EP-0269303-B1 | PIPERIDINE DERIVATIVE FOR TREATING PAIN | NOVO NORDISK A/S (DK) | 1993-08-04 | — | — | EP | claimed |
| EP-0223403-B1 | PIPERIDINE DERIVATIVE, ITS PREPARATION, AND ITS USE AS MEDICAMENT | BEECHAM GROUP PLC (GB) | 1993-08-04 | — | — | EP | claimed |
| US-4804669-A | Treatment of pain with a piperidine | A/S FERROSAN (DK) | 1989-02-14 | — | — | US | claimed |
| EP-0269303-A2 | Piperidine derivative for treating pain | NOVO NORDISK A/S (DK) | 1988-06-01 | — | — | EP | claimed |
| US-4721723-A | TRANS-4-(4'FLUOROPHENYL)3-(3',4' METHYLENEDIOXY PHENOXY METHYL PIPERIDINE | BEECHAM GROUP P.L.C. (GB) | 1988-01-26 | — | — | US | claimed |
| EP-0223403-A2 | Piperidine derivative, its preparation, and its use as medicament | BEECHAM GROUP PLC (GB) | 1987-05-27 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080187584-A1 | Stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof | CYP2D6, FKBP5, FKBP4 | SLC6A4 30/4885CYP3A4 40/4885GRK2 1125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.